ArriVent BioPharma, Inc Common Stock
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -34,978 | -31,399 | -66,772 | -23,705 |
EBIT | -33,623 | -66,772 | -23,705 | |
Net Income | -34,978 | -31,399 | -64,387 | -20,633 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -35,798 | -26,124 | -68,008 | -16,152 |
Cash | 112,672 | 112,765 | 49,865 | 74,293 |
Basic Shares | 41,912 | 35,006 | 33,899 | 33,581 |
Annual Financials
| Values in thousands | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|
Revenue | $0 | $0 | $0 |
EBITDA | -80,488 | -74,590 | -36,906 |
EBIT | -94,308 | -74,590 | -73,812 |
Net Income | -80,488 | -69,333 | -36,906 |
Net Change In Cash | 0 | 0 | 0 |
Free Cash Flow | -70,212 | -55,842 | -43,631 |
Cash | 74,293 | 150,389 | 163,372 |
Basic Shares | 31,469 | 31,956 | 33,493 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | -$0.83 |
2025-06-30 | -$0.90 |
2025-03-31 | -$1.90 |
2024-12-31 | -$0.60 |
